You are here: Home: PCU 3 | 2006: Stephen J Freedland, MD: Select publications

SELECT PUBLICATIONS

Freedland SJ et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294(4):433-9. Abstract

Goodin S et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005;23:3352-7. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Stephenson AJ et al. Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Proc ASCO 2006;Abstract 4514.

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract



PCU Think Tank

Home

Table of Contents

Editor
Neil Love, MD

INTERVIEWS

Stephen J Freedland, MD
- Select publications

Michael J Zelefsky, MD
- Select publications

Mario A Eisenberger, MD
- Select publications

Paul F Schellhammer, MD
- Select publications

Faculty Disclosures

CME Information

Editor's Office